Erasca, Inc.
ERAS
Kedudukan dalam Saham
#3362
Erasca, Inc. is a biopharmaceutical company in the clinical development stage,... Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
Harga Saham
$14.63
Modal Pasaran
$5.12B
Perubahan (1 hari)
7.41%
Perubahan (1 tahun)
494.70%
Negara
US
Perdagangan Erasca, Inc. (ERAS)
Kategori
Healthcare
Pendapatan untuk Erasca, Inc. (ERAS)
Pendapatan pada Jun 2026 TTM: $-287.22M
Menurut laporan kewangan terkini Erasca, Inc., pendapatan semasa syarikat ialah $-287.22M. Pada tahun 2023, syarikat memperoleh pendapatan sebanyak $-125.04M, peningkatan berbanding pendapatan pada tahun 2022 yang berjumlah $-242.81M. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Erasca, Inc. dari 2019 hingga 2026
Pendapatan pada akhir setiap tahun
| Tahun | Pendapatan | Ubah |
|---|---|---|
| 2026 (TTM) | $-287.22M | 77.68% |
| 2024 | $-161.65M | 29.28% |
| 2023 | $-125.04M | -48.50% |
| 2022 | $-242.81M | 97.78% |
| 2021 | $-122.76M | 20.76% |
| 2020 | $-101.66M | 744.35% |
| 2019 | $-12.04M | 0.00% |
Pendapatan untuk syarikat atau pesaing serupa
| Syarikat | Pendapatan | Perbezaan Pendapatan | Negara |
|---|---|---|---|
| $5.27B | -1,936.52% |
US
|
|
| $-3.09B | 974.77% |
US
|
|
| $-4.02B | 1,298.29% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -779.14% |
NL
|
